CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
CalciMedica (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright Global Investment Conference. CEO Rachel Leheny, Ph.D. will present on September 8, 2025, at 3:30 p.m. ET.
The presentation will be available via live webcast in the "IR Events and Presentations" section of CalciMedica's website, with a replay accessible for 90 days following the event.
CalciMedica (NASDAQ:CALC), una società biofarmaceutica in fase clinica che sviluppa terapie basate sull'inibizione dei canali CRAC, ha annunciato la sua partecipazione all'imminente H.C. Wainwright Global Investment Conference. La CEO Rachel Leheny, Ph.D. terrà una presentazione l'8 settembre 2025 alle 15:30 ET.
La presentazione sarà trasmessa in diretta via webcast nella sezione "IR Events and Presentations" del sito web di CalciMedica; la replica sarà disponibile per 90 giorni dopo l'evento.
CalciMedica (NASDAQ:CALC), una compañía biofarmacéutica en fase clínica que desarrolla terapias mediante inhibición de los canales CRAC, anunció su participación en la próxima H.C. Wainwright Global Investment Conference. La directora ejecutiva Rachel Leheny, Ph.D. presentará el 8 de septiembre de 2025 a las 3:30 p.m. ET.
La presentación se podrá ver en directo por webcast en la sección "IR Events and Presentations" del sitio web de CalciMedica; la repetición estará disponible durante 90 días tras el evento.
CalciMedica (NASDAQ:CALC)는 CRAC 채널 억제 치료법을 개발하는 임상 단계의 바이오제약회사로, 다가오는 H.C. Wainwright Global Investment Conference에 참가한다고 발표했습니다. CEO Rachel Leheny, Ph.D.가 2025년 9월 8일 오후 3시 30분(ET)에 발표합니다.
발표는 CalciMedica 웹사이트의 "IR Events and Presentations" 섹션에서 라이브 웹캐스트로 시청할 수 있으며, 이벤트 종료 후 90일간 재시청이 가능합니다.
CalciMedica (NASDAQ:CALC), une société biopharmaceutique en phase clinique développant des thérapies par inhibition des canaux CRAC, a annoncé sa participation à la prochaine H.C. Wainwright Global Investment Conference. La PDG Rachel Leheny, Ph.D. présentera le 8 septembre 2025 à 15h30 ET.
La présentation sera diffusée en direct via webcast dans la section "IR Events and Presentations" du site web de CalciMedica ; le replay sera accessible pendant 90 jours après l'événement.
CalciMedica (NASDAQ:CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das Therapien zur Hemmung von CRAC-Kanälen entwickelt, gab seine Teilnahme an der bevorstehenden H.C. Wainwright Global Investment Conference bekannt. CEO Rachel Leheny, Ph.D. wird am 8. September 2025 um 15:30 Uhr ET präsentieren.
Die Präsentation wird per Live-Webcast in der Rubrik "IR Events and Presentations" auf der Website von CalciMedica verfügbar sein; eine Aufzeichnung ist für 90 Tage nach der Veranstaltung abrufbar.
- None.
- None.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA –NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated respiratory failure. For more information, please visit www.calcimedica.com.
Contact Information
Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302542326.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the H.C. Wainwright Conference?
How can investors access CalciMedica's (CALC) H.C. Wainwright presentation?
What type of therapies is CalciMedica (CALC) developing?
Who will represent CalciMedica (CALC) at the H.C. Wainwright Conference?
